IDEXX Laboratories, Inc. $IDXX Shares Sold by Fiera Capital Corp

Fiera Capital Corp lessened its stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) by 25.1% in the 4th quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 97,760 shares of the company’s stock after selling 32,761 shares during the quarter. Fiera Capital Corp owned about 0.12% of IDEXX Laboratories worth $66,138,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently made changes to their positions in IDXX. Virtus Advisers LLC acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at approximately $26,000. Park Place Capital Corp acquired a new stake in shares of IDEXX Laboratories in the fourth quarter valued at approximately $29,000. WealthCollab LLC acquired a new stake in shares of IDEXX Laboratories in the second quarter valued at approximately $30,000. Caitong International Asset Management Co. Ltd acquired a new stake in shares of IDEXX Laboratories in the third quarter valued at approximately $36,000. Finally, Mowery & Schoenfeld Wealth Management LLC increased its holdings in shares of IDEXX Laboratories by 58.8% in the fourth quarter. Mowery & Schoenfeld Wealth Management LLC now owns 54 shares of the company’s stock valued at $37,000 after purchasing an additional 20 shares during the last quarter. Institutional investors and hedge funds own 87.84% of the company’s stock.

Analyst Ratings Changes

Several research firms recently commented on IDXX. Citigroup began coverage on IDEXX Laboratories in a report on Wednesday, April 15th. They issued a “neutral” rating and a $650.00 price target for the company. Wall Street Zen cut IDEXX Laboratories from a “buy” rating to a “hold” rating in a report on Saturday, April 25th. Stifel Nicolaus lowered their price objective on IDEXX Laboratories from $775.00 to $675.00 and set a “buy” rating for the company in a research report on Tuesday, March 31st. Piper Sandler lowered their price objective on IDEXX Laboratories from $775.00 to $750.00 and set a “neutral” rating for the company in a research report on Monday, February 9th. Finally, Weiss Ratings lowered IDEXX Laboratories from a “hold (c+)” rating to a “hold (c)” rating in a research report on Monday, May 11th. Seven analysts have rated the stock with a Buy rating and four have given a Hold rating to the company. According to data from MarketBeat.com, IDEXX Laboratories has a consensus rating of “Moderate Buy” and a consensus target price of $751.00.

IDEXX Laboratories Stock Performance

Shares of IDEXX Laboratories stock opened at $562.16 on Monday. The firm has a market capitalization of $44.34 billion, a price-to-earnings ratio of 41.40, a PEG ratio of 3.08 and a beta of 1.56. IDEXX Laboratories, Inc. has a fifty-two week low of $506.91 and a fifty-two week high of $769.98. The company has a debt-to-equity ratio of 0.19, a quick ratio of 0.82 and a current ratio of 1.12. The stock has a 50 day moving average of $563.05 and a 200 day moving average of $631.88.

IDEXX Laboratories (NASDAQ:IDXX) last issued its quarterly earnings data on Tuesday, May 5th. The company reported $3.47 earnings per share for the quarter, topping the consensus estimate of $3.41 by $0.06. The company had revenue of $1.14 billion during the quarter, compared to analyst estimates of $1.12 billion. IDEXX Laboratories had a return on equity of 70.87% and a net margin of 24.63%.The firm’s revenue for the quarter was up 14.3% compared to the same quarter last year. During the same period in the prior year, the business posted $2.91 earnings per share. IDEXX Laboratories has set its FY 2026 guidance at 14.450-14.900 EPS. As a group, research analysts predict that IDEXX Laboratories, Inc. will post 14.68 earnings per share for the current year.

IDEXX Laboratories Profile

IDEXX Laboratories, Inc (NASDAQ: IDXX) is a global developer, manufacturer and provider of diagnostic products and services primarily for the animal health, water testing and food safety markets. Headquartered in Westbrook, Maine, the company supplies in-clinic diagnostic instruments, consumables, reference laboratory testing and practice-management tools that support veterinarians, livestock and dairy producers, and utilities and food producers worldwide.

IDEXX’s product portfolio includes point-of-care tests and immunoassays designed for rapid diagnosis in veterinary clinics, in-clinic chemistry and hematology analyzers, automated urinalysis systems, and digital diagnostic solutions.